摘要
目的：探讨腺病毒介导Ｒｏｕｓ肉瘤病毒驱动的单纯疱疹病毒胸苷激酶（ＡＤＶ／ＲＳＶ－ｔｋ）基因及丙氧鸟苷（ＧＣＶ）治疗卵巢癌的有效性和毒性。方法：首先以卵巢浆液性腺癌细胞系Ｏｖ－ｃａ－２７７４建立荷人卵巢癌裸鼠腹水瘤模型，再分别单用ＡＤＶ／ＲＳＫ－ｔｋ或ＧＣＶ（单药组）或联合应用ＡＤＶ／ＲＳＫ－ｔｋ及ＧＣＶ（联合用药组）进行治疗。观察空白对照组、单药组及联合用药组裸鼠的平均生存时间及药物毒性。结果：单药组裸鼠在用药后１４．４±１．７天～１９．３±３．５天死亡，与空白对照组相比，差异无显著性。而联合用药组裸鼠的平均生存时间比单药组至少延长两倍，两组差异有显著性；开始用药时间越早，平均生存期越长；且疗效与用药剂量及裸鼠肿瘤负荷有依赖关系。结论：对荷人卵巢癌裸鼠腹水瘤模型的ＡＤＶ／ＲＳＴ－ｔｋ基因治疗是一种安全、有效的方法。
Objective: The efficacy and toxicity of adenovirusmediated transduction of herpes simplex virus thymidine kinase gene started by Rous sarcoma virus (ADV/RSVtk) followed by administration of ganciclovir (GCV) were studied in vivo. Methods: An animal model of human epithelial ovarian cancer was established in nude mice using the serous ovarian adenocarcinoma cell lines Ovca2774, then mice were treated by ADV/RSVTk and GCV, or GCV and HSVtk respectively. The average survival time of mice and toxicity were assessed.Results: The mice treated with GCV or HSV tk alone died from 14.4±1.7 to 19.3±3.5 days after treatment. The survival time had no difference with control group. The mice treated with ADV/RSVtk followed by GCV lived at least two times longer than controls and the difference in both groups was significant. The earlier the treatment began, the longer the average survival time was. Treatment efficacy was dependent on dose of ADV/RSVtk and tumor burden of mice. Conclusion: ADV/RSVtk gene therapy is a safe and efficient approach to ovarian cancer treatment in the experiment.
出处
《中华妇产科杂志》
CAS
CSCD
北大核心
1997年第12期712-714,I045,共4页
Chinese Journal of Obstetrics and Gynecology
